Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6105
Peer-review started: May 16, 2023
First decision: July 18, 2023
Revised: July 18, 2023
Accepted: August 17, 2023
Article in press: August 17, 2023
Published online: September 16, 2023
Processing time: 114 Days and 21.2 Hours
Various advances in immunotherapy against coronavirus disease 2019 (COVID-19) have emerged. Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Other antiviral therapy against COVID-19 includes remdesivir and favipiravir.
This study may change the protocol of treatment of COVID-19 patients.
The objectives are to compare the efficacy of antibodies cocktail (casirivimab and imdevimab), remdesivir, and favipravir in reducing the need for invasive mechanical ventilation.
The study design is a single-blind non-randomized controlled trial Mansoura University Hospital owns the study’s drugs. The duration of the study was about 6 mo after ethical approval.
Casirivimab and imdevimab cause less need for O2 therapy, and invasive mechanical ventilation, also they achieve less duration of this need than remdesivir and favipiravir.
Casirivimab and imdevimab achieve better clinical outcomes than remdesivir, and favipravir.
COVID-19 catastrophe causes progress in research works to find an end to this crisis. With ending of 2021 year.